Novartis Ag

Other

Irm LLC

Susan E Cellitti

Bernhard Hubert Geierstanger

Tetsuo Uno

Stuart Licht

Andreas Loew

Matthew T Burger

Shari Lynn Caplan

Michael P Cooke

Yunho Jin

Weijia Ou

Kathrin Tissot

Brian R Boettcher

Jan Grunewald

Siew Ho Schleyer

Norio Hamamatsu

Douglas S Daniels

Stephen Craig Weldon

Catrin Finner

Anthony E Boitano

Xueshi Hao

Ben Wen

HongNgoc Thi Pham

Tiffany Crossgrove

Hsien-Po Chiu

Si Tuen Lee-Hoeflich

Bernhard Hubert Geierstranger

The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Antibody drug conjugates for ablating hematopoietic stem cells

The present invention relates to the identification of dual function fusion proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating metabolic, cardiovascular, and endocrine conditions related to glucose and/or lipid homeostasis.

Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins

Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analog, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.

Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues

The present invention relates to dual function fusions proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.

Dual function fibroblast growth factor 21 proteins

Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analogue, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.

Growing community of inventors

San Diego, CA, United States of America

Susan E Cellitti